These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 266212)
1. 5'-deoxypyridoxal as a potential anti-sickling agent. Benesch R; Benesch RE; Edalji R; Suzuki T Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1721-3. PubMed ID: 266212 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of erythrocyte sickling in vitro by pyridoxal. Kark JA; Kale MP; Tarassoff PG; Woods M; Lessin LS J Clin Invest; 1978 Oct; 62(4):888-91. PubMed ID: 701485 [TBL] [Abstract][Full Text] [Related]
3. Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes. Beddell CR; Goodford PJ; Kneen G; White RD; Wilkinson S; Wootton R Br J Pharmacol; 1984 Jun; 82(2):397-407. PubMed ID: 6733364 [TBL] [Abstract][Full Text] [Related]
4. Pyridoxal phosphate as an antisickling agent in vitro. Kark JA; Tarassoff PG; Bongiovanni R J Clin Invest; 1983 May; 71(5):1224-9. PubMed ID: 6853710 [TBL] [Abstract][Full Text] [Related]
12. Schiff base adducts of hemoglobin. Modifications that inhibit erythrocyte sickling. Zaugg RH; Walder JA; Klotz IM J Biol Chem; 1977 Dec; 252(23):8542-8. PubMed ID: 925011 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. Safo MK; Kato GJ Hematol Oncol Clin North Am; 2014 Apr; 28(2):217-31. PubMed ID: 24589263 [TBL] [Abstract][Full Text] [Related]
14. Quantitative prediction of erythrocyte sickling for the development of advanced sickle cell therapies. Lu L; Li Z; Li H; Li X; Vekilov PG; Karniadakis GE Sci Adv; 2019 Aug; 5(8):eaax3905. PubMed ID: 31457104 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of erythrocyte sickling by thiol reagents. Garel MC; Domenget C; Galacteros F; Martin-Caburi J; Beuzard Y Mol Pharmacol; 1984 Nov; 26(3):559-65. PubMed ID: 6493211 [TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease. Xu GG; Pagare PP; Ghatge MS; Safo RP; Gazi A; Chen Q; David T; Alabbas AB; Musayev FN; Venitz J; Zhang Y; Safo MK; Abdulmalik O Mol Pharm; 2017 Oct; 14(10):3499-3511. PubMed ID: 28858508 [TBL] [Abstract][Full Text] [Related]
17. The mechanism of action of two anti-sickling agents: sodium cyanate and glyceraldehyde. Manning JM; Acharya AS Am J Pediatr Hematol Oncol; 1984; 6(1):51-4. PubMed ID: 6711764 [TBL] [Abstract][Full Text] [Related]
18. The sickling process in relation to clinical manifestations. Bellingham AJ J Clin Pathol Suppl (R Coll Pathol); 1974; 8():23-5. PubMed ID: 4536364 [TBL] [Abstract][Full Text] [Related]
19. Viscosity and filtrability measurements of sickle-cell suspensions in the development of anti-sickling drugs. Ohnishi ST Blood Cells; 1982; 8(1):79-87. PubMed ID: 7115980 [TBL] [Abstract][Full Text] [Related]